BACKGROUND:Ischemic mitral regurgitation, a complication of myocardial infarction and coronary artery disease more generally, is associated with a high mortality rate and is estimated to affect 2.8 million Americans. With 1-year mortality rates as high as 40%, recent practice guidelines of professional societies recommend repair or replacement, but there remains a lack of conclusive evidence supporting either intervention. The choice between therapeutic options is characterized by the trade-off between reduced operative morbidity and mortality with repair versus a better long-term correction of mitral insufficiency with replacement. The long-term benefits of repair versus replacement remain unknown, which has led to significant variation in surgical practice. METHODS AND RESULTS: This article describes the design of a prospective randomized clinical trial to evaluate the safety and effectiveness of mitral valve repair and replacement in patients with severe ischemic mitral regurgitation. This trial is being conducted as part of the Cardiothoracic Surgical Trials Network. This article addresses challenges in selecting a feasible primary end point, characterizing the target population (including the degree of mitral regurgitation) and analytical challenges in this high mortality disease. CONCLUSIONS: The article concludes by discussing the importance of information on functional status, survival, neurocognition, quality of life, and cardiac physiology in therapeutic decision making.
RCT Entities:
BACKGROUND:Ischemic mitral regurgitation, a complication of myocardial infarction and coronary artery disease more generally, is associated with a high mortality rate and is estimated to affect 2.8 million Americans. With 1-year mortality rates as high as 40%, recent practice guidelines of professional societies recommend repair or replacement, but there remains a lack of conclusive evidence supporting either intervention. The choice between therapeutic options is characterized by the trade-off between reduced operative morbidity and mortality with repair versus a better long-term correction of mitral insufficiency with replacement. The long-term benefits of repair versus replacement remain unknown, which has led to significant variation in surgical practice. METHODS AND RESULTS: This article describes the design of a prospective randomized clinical trial to evaluate the safety and effectiveness of mitral valve repair and replacement in patients with severe ischemic mitral regurgitation. This trial is being conducted as part of the Cardiothoracic Surgical Trials Network. This article addresses challenges in selecting a feasible primary end point, characterizing the target population (including the degree of mitral regurgitation) and analytical challenges in this high mortality disease. CONCLUSIONS: The article concludes by discussing the importance of information on functional status, survival, neurocognition, quality of life, and cardiac physiology in therapeutic decision making.
Authors: Robert O Bonow; Blase A Carabello; Chatterjee Kanu; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-08-01 Impact factor: 29.690
Authors: E A Grossi; J D Goldberg; A LaPietra; X Ye; P Zakow; M Sussman; J Delianides; A T Culliford; R A Esposito; G H Ribakove; A C Galloway; S B Colvin Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: A M Gillinov; P N Wierup; E H Blackstone; E S Bishay; D M Cosgrove; J White; B W Lytle; P M McCarthy Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: L Aklog; F Filsoufi; K Q Flores; R H Chen; L H Cohn; N S Nathan; J G Byrne; D H Adams Journal: Circulation Date: 2001-09-18 Impact factor: 29.690
Authors: O Alfieri; F Maisano; M De Bonis; P L Stefano; L Torracca; M Oppizzi; G La Canna Journal: J Thorac Cardiovasc Surg Date: 2001-10 Impact factor: 5.209
Authors: Emmanuel Messas; Bruno Pouzet; Bernard Touchot; J Luis Guerrero; Gus J Vlahakes; Michel Desnos; Philippe Menasché; Albert Hagège; Robert A Levine Journal: Circulation Date: 2003-09-09 Impact factor: 29.690
Authors: E Messas; J L Guerrero; M D Handschumacher; C Conrad; C M Chow; S Sullivan; A P Yoganathan; R A Levine Journal: Circulation Date: 2001-10-16 Impact factor: 29.690
Authors: L Menicanti; M Di Donato; A Frigiola; G Buckberg; C Santambrogio; M Ranucci; D Santo Journal: J Thorac Cardiovasc Surg Date: 2002-06 Impact factor: 5.209
Authors: Romain Capoulade; Xin Zeng; Jessica R Overbey; Gorav Ailawadi; John H Alexander; Deborah Ascheim; Michael Bowdish; Annetine C Gelijns; Paul Grayburn; Irving L Kron; Robert A Levine; Michael J Mack; Serguei Melnitchouk; Robert E Michler; John C Mullen; Patrick O'Gara; Michael K Parides; Peter Smith; Pierre Voisine; Judy Hung Journal: Circulation Date: 2016-10-25 Impact factor: 29.690
Authors: Irving L Kron; Judy Hung; Jessica R Overbey; Denis Bouchard; Annetine C Gelijns; Alan J Moskowitz; Pierre Voisine; Patrick T O'Gara; Michael Argenziano; Robert E Michler; Marc Gillinov; John D Puskas; James S Gammie; Michael J Mack; Peter K Smith; Chittoor Sai-Sudhakar; Timothy J Gardner; Gorav Ailawadi; Xin Zeng; Karen O'Sullivan; Michael K Parides; Roger Swayze; Vinod Thourani; Eric A Rose; Louis P Perrault; Michael A Acker Journal: J Thorac Cardiovasc Surg Date: 2014-11-06 Impact factor: 5.209